Lupus erythematosus - 紅斑狼瘡
References
Cutaneous lupus erythematosus (CLE) 的識別和分類提出了診斷挑戰，將其與皮膚受累的 systemic lupus erythematosus 區分開來。最近的研究揭示了 CLE 的遺傳、環境和免疫因素。藥物誘導已成為 CLE 最重要的觸發因素之一。治療包括局部和全身治療，包括有前景的生物製劑，如 belimumab, rituximab, ustekinumab, anifrolumab, and BIIB059 ，並在臨床試驗中證明了療效。
Diagnostic challenges exist in better defining cutaneous lupus erythematosus (CLE) as an independent disease distinct from systemic lupus erythematosus with cutaneous features and further classifying CLE based on clinical, histological, and laboratory features. Recent mechanistic studies revealed more genetic variations, environmental triggers, and immunologic dysfunctions that are associated with CLE. Drug induction specifically has emerged as one of the most important triggers for CLE. Treatment options include topical agents and systemic therapies, including newer biologics such as belimumab, rituximab, ustekinumab, anifrolumab, and BIIB059 that have shown good clinical efficacy in trials.
Diagnostic challenges exist in better defining cutaneous lupus erythematosus (CLE) as an independent disease distinct from systemic lupus erythematosus with cutaneous features and further classifying CLE based on clinical, histological, and laboratory features. Recent mechanistic studies revealed more genetic variations, environmental triggers, and immunologic dysfunctions that are associated with CLE. Drug induction specifically has emerged as one of the most important triggers for CLE. Treatment options include topical agents and systemic therapies, including newer biologics such as belimumab, rituximab, ustekinumab, anifrolumab, and BIIB059 that have shown good clinical efficacy in trials.
Cutaneous lupus erythematosus (CLE) 涵蓋各種皮膚問題，其中一些可能與更廣泛的健康問題有關。它分為不同的類型，例如 acute CLE (ACLE) , sub-acute CLE (SCLE) , and chronic CLE (CCLE) 。 CCLE 包括 discoid lupus erythematosus (DLE) , LE profundus (LEP) , chilblain cutaneous lupus, and lupus tumidus 。
Cutaneous lupus erythematosus (CLE) encompasses a wide range of dermatologic manifestations, which may or may not be associated with the development of systemic disease. Cutaneous lupus is divided into several sub-types, including acute CLE (ACLE), sub-acute CLE (SCLE) and chronic CLE (CCLE). CCLE includes discoid lupus erythematosus (DLE), LE profundus (LEP), chilblain cutaneous lupus and lupus tumidus.
Cutaneous lupus erythematosus (CLE) encompasses a wide range of dermatologic manifestations, which may or may not be associated with the development of systemic disease. Cutaneous lupus is divided into several sub-types, including acute CLE (ACLE), sub-acute CLE (SCLE) and chronic CLE (CCLE). CCLE includes discoid lupus erythematosus (DLE), LE profundus (LEP), chilblain cutaneous lupus and lupus tumidus.
Lupus erythematosus 是一組可影響身體不同部位的自體免疫疾病。有些類型，如 systemic lupus erythematosus (SLE) ，影響多個器官，而其他類型，如 cutaneous lupus erythematosus (CLE) ，主要影響皮膚。我們根據臨床症狀、組織檢查和血液檢查對不同類型的 CLE 進行分類，但個體之間存在很大差異。皮膚問題通常是由於暴露在陽光下、吸煙或某些藥物等因素造成的。
Lupus erythematosus comprises a spectrum of autoimmune diseases that may affect various organs (systemic lupus erythematosus [SLE]) or the skin only (cutaneous lupus erythematosus [CLE]). Typical combinations of clinical, histological and serological findings define clinical subtypes of CLE, yet there is high interindividual variation. Skin lesions arise in the course of triggers such as ultraviolet (UV) light exposure, smoking or drugs
Lupus erythematosus comprises a spectrum of autoimmune diseases that may affect various organs (systemic lupus erythematosus [SLE]) or the skin only (cutaneous lupus erythematosus [CLE]). Typical combinations of clinical, histological and serological findings define clinical subtypes of CLE, yet there is high interindividual variation. Skin lesions arise in the course of triggers such as ultraviolet (UV) light exposure, smoking or drugs
紅斑狼瘡 (lupus erythematosus) 的病因尚不清楚。在同卵雙胞胎中，如果其中一方受到影響，另一方也有 24% 的機會受到影響。女性性激素、陽光、吸煙、維生素 D 缺乏和某些感染也被認為會增加患病風險。
治療方法可能包括非類固醇抗發炎藥、皮質類固醇、免疫抑制劑、羥氯奎寧和甲氨蝶呤。儘管皮質類固醇有效，但長期使用會產生副作用。